心肌缺血后靶向Gβγ-GRK2抑制或消除活化成纤维细胞可减轻心衰进展
该研究探讨心肌缺血再灌注损伤后抑制Gβγ-GRK2或特异性消融活化成纤维细胞中的GRK2能否减轻病理性肌成纤维细胞活化和心脏重塑。结果表明,损伤后1周启动小分子Gβγ-GRK2抑制可保护心脏收缩功能并减少纤维化重塑;活化成纤维细胞特异性GRK2消融同样产生显著功能保护并减少肌成纤维细胞转化和纤维化。
要点
- 心肌缺血后1周启动Gβγ-GRK2抑制可保护心脏收缩力并减少纤维化重塑。
- 活化成纤维细胞中GRK2消融可减少肌成纤维细胞转化和纤维化并改善功能。
- Gβγ-GRK2抑制可减弱终末期心衰患者心脏成纤维细胞的活化特征。
核心结论
- 心肌损伤后抑制Gβγ-GRK2或消融活化成纤维细胞中的GRK2可减轻病理性肌成纤维细胞活化、间质纤维化和心衰进展。
研究设计与样本
- 研究采用小分子Gβγ-GRK2抑制,单独或联合活化成纤维细胞特异性或心肌细胞特异性GRK2消融,均于心肌缺血再灌注损伤后启动。
主要发现
- 缺血再灌注损伤后1周启动小分子Gβγ-GRK2抑制在慢性心衰模型中具有心脏保护作用,包括保留心脏收缩力和减少心脏纤维化重塑。
- 在心肌细胞特异性GRK2消融小鼠中,缺血再灌注后1周启动全身小分子Gβγ-GRK2抑制仍显示显著心脏保护,提示心肌细胞之外的保护作用。
- 缺血再灌注损伤后诱导性消融活化成纤维细胞中的GRK2可产生显著功能心脏保护,并减少肌成纤维细胞转化和纤维化。
- 在活化成纤维细胞中GRK2消融的小鼠中,缺血再灌注后1周启动全身小分子Gβγ-GRK2抑制几乎不提供额外保护。
- Gβγ-GRK2抑制可显著减弱从终末期心衰患者分离的衰竭人类心脏成纤维细胞的活化特征。
临床怎么用
- 对于心肌缺血后心衰进展的患者,靶向Gβγ-GRK2或活化成纤维细胞中的GRK2可能成为减轻纤维化重塑的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac fibroblasts are a critical cell population responsible for myocardial extracellular matrix homeostasis. Upon injury or pathological stimulation, these cells transform to an activated myofibroblast state and play a fundamental role in myocardial fibrosis and remodeling. Chronic sympathetic overstimulation, a hallmark of heart failure (HF), induces pathological signaling through G protein βγ (Gβγ) subunits and their interaction with G protein-coupled receptor kinase 2 (GRK2). OBJECTIVES: This study investigated the hypothesis that Gβγ-GRK2 inhibition and/or ablation after myocardial injury would attenuate pathological myofibroblast activation and cardiac remodeling. METHODS: The therapeutic potential of small molecule Gβγ-GRK2 inhibition, alone or in combination with activated fibroblast- or myocyte-specific GRK2 ablation-each initiated after myocardial ischemia-reperfusion (I/R) injury-was investigated to evaluate the possible salutary effects on post-I/R fibroblast activation, pathological remodeling, and cardiac dysfunction. RESULTS: Small molecule Gβγ-GRK2 inhibition initiated 1 week post-injury was cardioprotective in the I/R model of chronic HF, including preservation of cardiac contractility and a reduction in cardiac fibrotic remodeling. Systemic small molecule Gβγ-GRK2 inhibition initiated 1 week post-I/R in cardiomyocyte-restricted GRK2 ablated mice (also post-I/R) still demonstrated significant cardioprotection, which suggested a potential protective role beyond the cardiomyocyte. Inducible ablation of GRK2 in activated fibroblasts (i.e., myofibroblasts) post-I/R injury demonstrated significant functional cardioprotection with reduced myofibroblast transformation and fibrosis. Systemic small molecule Gβγ-GRK2 inhibition initiated 1 week post-I/R provided little to no further protection in mice with ablation of GRK2 in activated fibroblasts alone. Finally, Gβγ-GRK2 inhibition significantly attenuated activation characteristics of failing human cardiac fibroblasts isolated from end-stage HF patients. CONCLUSIONS: These findings suggested consideration of a paradigm shift in the understanding of the therapeutic role of Gβγ-GRK2 inhibition in treating HF and the potential therapeutic role for Gβγ-GRK2 inhibition in limiting pathological myofibroblast activation, interstitial fibrosis, and HF progression.
引用
- Travers JG, Kamal FA, Valiente-Alandi I, et al. Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression. J Am Coll Cardiol. 2017. PMID: 28818206. doi:10.1016/j.jacc.2017.06.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。